Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome -- Ignore unavailable to you. Want to Upgrade?

To: G-MAN who wrote (798)	9/3/1999 10:25:00 PM
From: Donald Gravenor	Respond to of 900

In Canada, Shering markets a drug called Caelix, and encapsulated adriamycin (doxorubicin), called doxil in the US. I've given it for Kaposi's sarcomas (the original indication), and have now prescribed it for a non-Hodgkin's lymphoma patient who had a decreased cardiac ejection fraction from previous adriamycin therapy. I'm not sure what the differences are between evacet and doxil/caelix are, if any. Moreover, there is already one liposomally encapsulated adria on the market---if a second one comes along, it might have to compete on price. Tell me if there are differences to these two drugs.